Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
about
Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenograftsNew method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug.Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapyMechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destructionThe vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.Antiproliferative activity of Cyanophora paradoxa pigments in melanoma, breast and lung cancer cells.Novel methods to incorporate photosensitizers into nanocarriers for cancer treatment by photodynamic therapyPhotodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report.Adjuvant intraoperative photodynamic therapy in head and neck cancer.Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.Comparison of singlet oxygen threshold dose for PDT.Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib studyConfocal fluorescence imaging enables noninvasive quantitative assessment of host cell populations in vivo following photodynamic therapy.A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.Efficacy of 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a in photodynamic therapy of human esophageal squamous cancer cellsComparative positron-emission tomography (PET) imaging and phototherapeutic potential of 124I- labeled methyl- 3-(1'-iodobenzyloxyethyl)pyropheophorbide-a vs the corresponding glucose and galactose conjugatesPhotodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity.Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.Interaction and oxidative damage of DVDMS to BSA: a study on the mechanism of photodynamic therapy-induced cell death.Dye Sensitizers for Photodynamic TherapyIn vitro cellular uptake and dimerization of signal transducer and activator of transcription-3 (STAT3) identify the photosensitizing and imaging-potential of isomeric photosensitizers derived from chlorophyll-a and bacteriochlorophyll-a.Synthesis, spectroscopic, and in vitro photosensitizing efficacy of ketobacteriochlorins derived from ring-B and ring-D reduced chlorins via pinacol-pinacolone rearrangement.On the in vivo photochemical rate parameters for PDT reactive oxygen species modeling.Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles.Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy.Photodynamic activity of BAM-SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, in tumour-bearing nude mice.Synthesis of Tumor-avid Photosensitizer-Gd(III)DTPA conjugates: impact of the number of gadolinium units in T1/T2 relaxivity, intracellular localization, and photosensitizing efficacy.Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivoProteomic approaches in understanding action mechanisms of metal-based anticancer drugs.Indium as a central metal enhances the photosensitizing efficacy of benzoporphyrin derivatives.Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent.Cationic dendritic starch as a vehicle for photodynamic therapy and siRNA co-delivery.
P2860
Q30611957-9692EDF6-2DE1-491C-B99B-CF78161D0887Q33271133-FE7D6B63-6A0C-43ED-8FD1-CDEA674ED5CEQ33553797-0839C9A5-2F75-4933-881F-9EA13487398DQ33939506-47D89ECE-6E5E-4B35-AAAA-EE3EE3D6C0B8Q33961848-D6BDED41-3900-49A7-841B-0A71F4738D12Q34038770-DA290C61-2FBC-4ACB-8F5F-4BFD2494DC48Q34068186-E94FC242-7C0C-44DF-9FA5-482F8173799AQ34068196-1081C129-5608-4E17-A16E-E4117AE47865Q34240972-EEDE1880-1E3A-47FA-9C40-F1497356ACE2Q34836855-3A67A8A9-4273-4779-A470-CC7C3925E55CQ35623101-015BB059-E4A5-45EE-81E3-514E8B9709BEQ35624561-E77A170F-A28C-42C8-9215-18DC1BE9839BQ35842215-57D09C03-6F89-4B93-8699-C2ABC4AB3E15Q36329636-8F67356A-E615-4D09-AC29-9E2A62BD7578Q36510592-ED2F350B-316F-4D4E-9F81-8D022FD94EC6Q37229356-552AA415-103A-450C-82EE-4481DA8A477AQ37235473-5B876E60-720F-4066-AC91-2365DC31B39CQ37411837-C7BFF87B-A9D8-4763-AE1D-461FE5EF3FC1Q37547850-7A3DC5DC-D4DB-4336-9D44-9C9C93BFBAE8Q37676077-7A535B83-AC27-4E69-9540-4B7C0B11BCC5Q37676323-9CEA856A-D686-4BDA-89BA-DE7E733B3264Q38624133-D24615F3-B52F-4C24-B84C-21CF9E1A73CAQ38646915-9AD77123-3E44-4F55-9E20-680614189251Q38874307-18D1E408-4E07-444A-8BED-152B645781BCQ38976558-A358FF5F-B31C-48B6-B951-801301021407Q39437627-4BB689B0-8DA7-47A9-B845-2DB80827FBAAQ39518754-05CDE928-DE8A-4413-A6AB-D977048CE508Q39542782-E966EBA9-8CF4-4D76-A81F-AEB6DA588650Q39715385-E812B5A3-15EA-48E8-8C87-057EE9FE6DFAQ39840930-BD1DF05B-2C00-4E97-A97B-135261845E55Q40064331-087627C8-42B0-4CF9-B77C-E26618E8C23BQ42184734-D30F77EE-8DE9-4964-81B2-3658ADB23EACQ42528833-E80AB310-5294-4B39-87F6-E4EE422E3EF4Q50990014-A53992C8-63A6-4A83-A24E-5629834C65B6
P2860
Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Population pharmacokinetics of ...... phorbide-a in cancer patients.
@en
Population pharmacokinetics of ...... phorbide-a in cancer patients.
@nl
type
label
Population pharmacokinetics of ...... phorbide-a in cancer patients.
@en
Population pharmacokinetics of ...... phorbide-a in cancer patients.
@nl
prefLabel
Population pharmacokinetics of ...... phorbide-a in cancer patients.
@en
Population pharmacokinetics of ...... phorbide-a in cancer patients.
@nl
P2093
P1433
P1476
Population pharmacokinetics of ...... ophorbide-a in cancer patients
@en
P2093
Allan R Oseroff
David A Bellnier
Gregory M Loewen
Hector Nava
Ravindra K Pandey
Takaaki Tsuchida
Thomas J Dougherty
William R Greco
P304
P407
P577
2003-04-01T00:00:00Z